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Background. Immunosuppressive therapy for antineutrophil cytoplasmic antibody-associated vasculitis has been associated with
increased malignancy risk. Objectives. To quantify the cancer risk associated with contemporary cyclophosphamide-sparing
protocols. Methods. Patients from the Norwegian Kidney Biopsy Registry between 1988 and 2012 who had biopsy-verified pauci-
immune glomerulonephritis and positive antineutrophil cytoplasmic antibody (ANCA) serology were included. Standardised
incidence ratios (SIRs) were calculated to compare the study cohort with the general population. Results.The study cohort included
419 patients. During 3010 person-years, cancer developed in 41 patients (9.79%); the expected number of cancer cases was 37.5
(8.95%). The cohort had SIRs as follows: 1.09, all cancer types (95% CI, 0.81 to 1.49); 0.96, all types except nonmelanoma skin
cancer (95% CI, 0.69 to 1.34); 3.40, nonmelanoma skin cancer (95% CI, 1.62 to 7.14); 3.52, hematologic cancer (95% CI, 1.32 to
9.37); 2.12, posttransplant cancer (95% CI, 1.01 to 4.44); and 1.53, during the 1–5-year follow-up after diagnosis (95% CI, 1.01 to
2.32). Conclusions. Cancer risk did not increase significantly in this cohort with ANCA-associated glomerulonephritis. However,
increased risk of nonmelanoma skin cancer, posttransplant cancer, and hematologic cancer indicates an association between
immunosuppression and malignancy.
1. Introduction
Historically, antineutrophil cytoplasmic antibody- (ANCA-)
associated vasculitis (AAV) was a fatal disease. The intro-
duction of cyclophosphamide (CYC) treatment in the 1960s
improved the prognosis and made long-term survival pos-
sible for patients with AAV [1, 2]. However, evidence soon
emerged that the long-term survival of patientswithAAVwas
associated with significant morbidity including a substan-
tially increased cancer risk [3–7]. Immunosuppressive ther-
apy using CYC was particularly associated with malignancy.
Although the severe adverse effects have elicited a search for
less toxic treatment regimens, CYC still remains the first-line
drug [8].
High occurrence of cancer has been demonstrated in
patients with AAV treated with cumulative CYC doses
exceeding 36 g [9–11] or when the treatment duration lasted
formore than a year [4, 12–14]. In the current clinical practice,
cumulative CYC doses and treatment duration rarely exceed
these limits [15–18], which questions the relevance of pre-
vious CYC-associated increased cancer risk observations in
patientswithAAV.There is a relative paucity of data regarding
cancer risk in AAV patients treated with current therapy pro-
tocols, and, to our knowledge, only 4 studies have published
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such data [5, 11, 13, 19]. In these studies, increased incidence
of malignancy was observed. After excluding nonmelanoma
skin cancer (NMSC) from the analyses, the incidence of
malignancy no longer significantly increased in any of these
investigations. However, these 4 studies were relatively small,
with a limited statistical power to detect small- to medium-
range associations between cancer and AAV. Furthermore,
most of these reports are single-center studies, which limits
their generalizability.
Interestingly, in the most recent study, the standardised
incidence ratio (SIR) of all cancer types treated with CYC
was 4.61 (95% confidence interval (CI) 1.16 to 39.38) times
higher than that with rituximab-based therapy. However,
after excluding NMSC from their analysis, the risk was only
1.30 (95% CI not reported) times higher with CYC compared
with rituximab-based therapy [19].
To further investigate the association of cancer and AAV,
we analysed data from theNorwegianKidneyBiopsyRegistry
(NKBR) and the Norwegian Cancer Registry. Additionally,
we merged data from the present and the 4 recent studies on
this topic and investigated the cancer risk in a total of 1532
patients with AAV diagnosed after 1988.
2. Materials and Methods
The study was approved by the Regional Committees for
Medical and Health Research Ethics (REC South-East 2013/
1083).
2.1. Study Population and Registries. The NKBR was estab-
lished in 1988. We estimate that ∼90% of all kidney biopsies
are registered. The registry contains morphological, labo-
ratory, and clinical data collected when the biopsy was
performed. The Norwegian Cancer Registry was established
in 1953. Reporting to this registry is mandatory and based
on reports from clinical and pathological departments and
death certificates. A near complete registration (98-99%)
of solid tumors, except for basal skin cell carcinomas, is
documented [20]. Annual sex-specific incidence rates for
cancer and cancer subtypes are available for age groups and
time periods in 5-year intervals. These data allow for an
accurate calculation of the expected cancer case numbers in
the study cohort. The Norwegian Cause of Death Registry
is part of Statistics Norway and based on the mandatory
Norwegian death certificate. The Norwegian Renal Registry
was established in 1980 and has registered all patients with
end-stage renal disease, defined by the commencement of
maintenance dialysis or receiving kidney transplantation.
2.2. Data Collection and Definitions. We included patients
registered in theNKBRanddiagnosed from 1988 to 2012, with
a pauci-immune necrotising glomerulonephritis and a posi-
tive ANCA serology. Patients with cancer prior to the AAV
diagnosis were excluded. Baseline clinical data, including sex,
age, ANCA specificity, and estimated glomerular filtration
rate (eGFR) (determined by theModification of Diet in Renal
Disease equation) [21] were obtained from the NKBR. The
primary study end-point was incidence of cancer. By using
the unique 11-digit Norwegian personal number, the study
cohort was linked with the Norwegian Cancer Registry to
identify the cancer incidence. Causes of deaths in the study
cohort were identified through linkage with the Norwegian
Cause of Death Registry and classified as vascular, malignant,
infectious, or active inflammation and other causes. The
observation period was from the kidney biopsy date to
incident cancer, end of 2013, or death, whichever came first.
Patients with end-stage renal disease and those receiving
kidney transplants were identified through record linkage
with the Norwegian Renal Registry. When we calculated the
cancer risk in transplanted patients, the observation period
started from the kidney transplantation date.
2.3. SIR Calculation. We calculated the SIR as the ratio
between the observed and expected cancer case numbers in
the cohort. The expected cancer case number was calculated
as follows: first, the number of person-years was calculated
in the cohort, stratified by 5-year age groups and 1-year time
periods. Second, this person-time was multiplied with the
corresponding incidence rate in the general population to get
the expected number of cases in each age group and 1-year
period. The total number of expected cancer cases was then
calculated as the sum of expected cases across age groups and
time periods. The observed cancer case number was deter-
mined by record linkage of the study cohort and the Nor-
wegian Cancer Registry using the 11-digit unique Norwegian
personal number. A Poisson distribution of cancer incidence
was assumed when 95% CIs were calculated. We calculated
the SIR throughout the study period and stratified in accor-
dance with disease duration periods (0-1, 1–5, 5–10, and >10
years after kidney biopsy), sex, ANCA specificity [cytoplas-
mic ANCA (C-ANCA)/proteinase 3 ANCA (PR3-ANCA)
or perinuclear ANCA (P-ANCA)/myeloperoxidase ANCA
(MPO-ANCA)], time periods (1988–2002 and 2003–2012),
and posttransplantation observation period.
2.4. Pooled Analysis. A systematic PubMed search was con-
ducted to identify previous studies reporting the cancer risk
in patients with AAV diagnosed after 1988. The search was
restricted to papers published in English language. Studies
who do not report SIR data were excluded. The SIRs were
calculated as the sum of the observed cancer cases divided
by that of the expected cancer cases in all studies.
2.5. Treatment. Information regarding cumulative CYC
doses administered to the patients is not available in the
NKBR. In a previous Norwegian study including patients
with Wegener’s granulomatosis diagnosed between 1988 and
1998, the majority of patients received intravenous CYC with
a median cumulative dose of 17 g. In patients receiving oral
CYC, themedian cumulative dose was 48 g [22].Most centers
since approximately 2003 have substituted CYC with aza-
thioprine for maintenance treatment, substantially lowering
the exposure to CYC [23]. In some patients, rituximab has
been used for induction and maintenance treatment. Some
patients have also received plasma exchange treatments [24].
2.6. Statistical Analyses. Continuous variables were ex-
pressed as medians with 25th and 75th percentiles and
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Table 1: Baseline demographics of 419 Norwegian patients with AAV.
Characteristic Total Nonmalignancy Malignancy 𝑝 value
Age (median, IQR) 62 (49–72) 61 (48–72) 65 (56–73) 0.04
Male sex (%) 229 (55%) 200 (53%) 29 (71%) 0.03
eGFR (median, IQR) 23 (11–46) 24 (11–47) 19 (9–39) 0.29
C-ANCA/PR3-ANCA 237 (57%) 213 (56%) 24 (59%) 0.89
AAV, ANCA-associated vasculitis; IQR, interquartile range; eGFR, estimated glomerular filtration rate, mL/min/1.73m2; C-ANCA, cytoplasmic ANCA; PR3-
ANCA, proteinase 3 ANCA.
categorical variables as numbers (%). Comparisons of con-
tinuous and categorical variables in the baseline characteris-
tics were calculated using the Mann–Whitney U test and the
𝑋2 or Fisher’s exact test, respectively. A two-tailed 𝑝 value of
≤0.05 and 95% CI was considered statistically significant. All
statistical analyses were performed using the SPSS software,
V.23, and STATA software, V.14.
3. Results
3.1. Baseline Characteristics. Between 1988 and 2012, 454
patients diagnosed with AAV and glomerulonephritis were
identified. Of these, 35 were excluded as a result of cancer
diagnosis prior to the observation period. Thus, 419 patients
were included in the study cohort. As shown in Table 1, the
median age in the cohort was 62 years [interquartile range,
48 to 72 years], and 229 (55%) were men. The median eGFR
at the time of kidney biopsy was 23mL/min/1.73m2 (inter-
quartile range, 11 to 46). A positive C-ANCA/PR3-ANCAwas
found in 237 (57%) and P-ANCA/MPO-ANCA in 183 (43%)
patients.
The median length of follow-up was 5.7 years (interquar-
tile range, 2.8 to 11.3). The mean length of follow-up was
7.2 years (standard deviation, 5.8), and the total number of
person-years of observation was 3010. A total of 148 (35%)
patients died during the observation period. Causes of deaths
are registered for 138 patients, of which 69 (50%) died from
infectious disease or active inflammation/vasculitis, 36 (26%)
cardiovascular disease, 12 (9%) malignancy, and 21 (15%)
from other causes. Kidney transplantation was performed in
60 (14%) patients.
3.2. Observed Cancer Cases. During follow-up, 46 cancer
cases were reported in 41 (9.5%) patients. The first occurring
cancer cases were as follows: NMSC (7 cases), lung (7),
prostate (5), hematologic (4), urinary bladder and ureter (3),
rectum (3), colon (2), uterus (2), central nerve system (2),
unknown primary site (2), thyroid (1), ovary (1), lymphoma
(1), and pancreas (1). Five patients had 2 distinct cancer
diagnoses; the second occurring cancer cases were as follows:
lung (1), NMSC (1), prostate (1), hematologic (1), and stomach
(1). Seven patients who received transplants were diagnosed
with cancer; the first occurring cancer cases were as follows:
lung (4), prostate (1), lymphoma (1), and NMSC (1). Two of
the 5 patients with 2 distinct cancers underwent transplant,
with the cases of secondary cancer involving the prostate and
lungs.
3.3. Comparison of Patients with and without Cancer. The
comparison of the patients with and without cancer during
follow-up is shown in Table 1. The patients with cancer were
significantly older [65 years versus 61 years (𝑝 = 0.04)]
at the time of AAV diagnosis, and a significantly higher
percentage were men (71% versus 53% (𝑝 = 0.03)). There
were no significant differences in eGFR andANCA specificity
between those with cancer and those without cancer during
follow-up. A higher percentage of patients with cancer died
during follow-up [25 (61%) versus 123 (33%) (𝑝 < 0.001)].
3.4. Comparison with the General Population. As shown in
Table 2(a), the SIR of overall malignancy was 1.09 (95% CI
0.81 to 1.49). The SIR of all cancer types, except NMSC, was
0.96 (95% CI 0.69 to 1.34). In the 1–5-year period after AAV
diagnosis, the cancer risk in the study cohort significantly
increased compared to that in the general population (SIR,
1.53; 95% CI 1.01 to 2.32). The SIR did not increase in the first
year or >5 years of follow-up after AAV diagnosis. In gender-
, ANCA-, and time period specificity-stratified analyses, SIR
of cancer was not significantly increased for males of 1.27
(95% CI 0.88 to 1.83), in the C-ANCA/PR3-ANCA positive
group of 1.17 (95% CI 0.78 to 1.74) and in the 1988–2002 time
period of 1.14 (95% CI 0.78 to 1.68). Compared to the general
population, the transplanted patients in the study cohort had
a significantly increased malignancy risk (SIR, 2.12; 95% CI
1.01 to 4.44), whereas the nontransplanted patients had no
increased risk (SIR, 0.99; 95% CI 0.71 to 1.39).
The SIR calculation for the most common site-specific
cancer cases showed significantly increased risks of NMSC
(SIR, 3.40; 95% CI 1.62 to 7.14) and hematologic malignancies
(SIR, 3.52; 95% CI 1.32 to 9.37). The SIR did not significantly
increase in any other site-specific cancer type (Table 2(b)).
3.5. Pooled Analysis of the 5 Cohort Studies. The separate and
merged SIRs of all cancer types in the present and the 4
previously reported studies are shown in Table 3 and Figure 1.
This analysis included a total of 1532 patients, 8801 patient-
years of observation, and 236 cancer cases. The merged SIR
of all cancer types was 1.72 (95% CI 1.51 to 1.95) and that of all
cancer types, except NMSC, was 1.21 (95% CI 1.01 to 1.45).
4. Discussion
In the present study, there was no statistically significant
increase in the cancer incidence in the patients with AAV and
glomerulonephritis compared to the age- and sex-matched
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Table 2
(a) Standardised incidence ratios for cancers in all sites in the study population
Characteristic Observed Expected SIR 95% CI
All 41 37.5 1.09 0.81 to 1.49
Non-NMSC 34 35.4 0.96 0.69 to 1.34
Sex
Male 29 22.9 1.27 0.88 to 1.83
Female 12 14.6 0.82 0.47 to 1.44
Follow-up period
0-1 year 3 4.3 0.70 0.22 to 2.16
1–5 years 22 14.4 1.53 1.01 to 2.32
5–10 years 11 11.1 0.99 0.55 to 1.78
>10 years 5 7.6 0.66 0.27 to 1.57
Transplantation
Yes 7 3.3 2.12 1.01 to 4.44
No 34 34.2 0.99 0.71 to 1.39
ANCA serology
C-ANCA/PR3-ANCA 24 20.6 1.17 0.78 to 1.74
P-ANCA/MPO-ANCA 17 16.9 1.01 0.63 to 1.62
Study period
1988–2002 26 22.7 1.14 0.78–1.68
2003–2012 15 14.8 1.02 0.61–1.68
SIR, standardised incidence ratio; 95%CI, 95% confidence interval; NMSC, nonmelanoma skin cancer; C-ANCA, cytoplasmic ANCA; PR3-ANCA, proteinase
3 ANCA; P-ANCA, perinuclear ANCA; MPO-ANCA, myeloperoxidase ANCA.
(b) Standardised incidence ratios for the most common organ-specific cancers in the study population
Organs Observed Expected SIR 95% CI
NMSC 7 2.1 3.40 1.62 to 7.14
Hematologic 4 1.1 3.52 1.32 to 9.37
Lung 7 4.0 1.73 0.83 to 3.63
Colon 2 1.2 1.73 0.43 to 6.93
Urothelium 3 2.0 1.48 0.47 to 4.59
Prostate 5 7.0 0.72 0.30 to 1.73
NHL 1 1.2 0.86 0.12 to 6.12
SIR, standardised incidence ratio; 95% CI, 95% confidence interval; NMSC, nonmelanoma skin cancer; NHL, non-Hodgkin lymphoma.
Heijl et al. (2011)
Zycinska et al. (2013)
Rahmattulla et al. (2015)












Figure 1: Forest plot showing the risk of malignancy except for nonmelanoma skin cancer in observational studies of patients with ANCA-
associated vasculitis. SIR, standardised incidence ratio; 95% CI, 95% confidence interval.
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general population (SIR, 1.09; 95%CI 0.89 to 1.49). Excluding
the study by Holle et al. that reported an SIR of 0.82 (95%
CI 0.45 to 1.38) [25], most previous studies, including those
investigating patients with AAV diagnosed after 1988, have
reported a significantly increased cancer risk [3–5, 9, 11, 13, 14,
19]. A couple ofmethodological discrepanciesmight partially
explain the contrasting findings between the present and the
majority of previous studies. First, basal skin cell carcinomas
are not registered in theNorwegianCancer Registry andwere
thus excluded in our analysis. Second, among patients with
diagnoses of several cancers, we only included the primary
cancer when calculating the SIRs. In contrast, other studies
have included subsequent cancer cases, particularly NMSC,
in their SIR estimates.
The studies investigating cancer incidences in patients
with AAV diagnosed after 1988 reflect contemporary treat-
ment regimens, in which NMSC accounts for the majority of
the observed increased malignancy risk [5, 11, 13, 19]. In the
present study, the SIR decreased from 1.09 to 0.96 (95% CI
0.69 to 1.34) whenNMSC cases were excluded. Further, in the
pooled analysis (Table 3), the SIR decreased from 1.72 (95%CI
1.51 to 1.95) to 1.21 (95%CI 1.01 to 1.45) after excludingNMSC.
Moreover, part of the residual cancer risk after excluding
NMSC can be attributed to posttransplantmalignancies, with
the SIR posttransplant of 2.12 (95% CI 1.01 to 4.44) in the
present study and 4.31 (95% CI 1.17 to 11.04) in that by Van
Daalen et al. [19].
In the organ-specific subanalysis, the SIR of NMSC
was 3.40 (95% CI 1.62 to 7.14), which is consistent with
that of previous studies [5, 9, 11, 13, 14, 19]. An increased
risk of NMSC is observed in immunocompromised patients
and associated with both environmental factors as chronic
human papillomavirus infection [26–29] and a direct effect
of individual immunosuppressant, for example, azathioprine
[19, 30]. A significantly increased hematologic cancer riskwas
also found (SIR, 3.52; 95% CI 1.32 to 9.37). Traditionally, CYC
use was associated with a very high risk of acutemyelogenous
leukemia [9, 14, 31]. Interestingly, no case of this cancer form
was observed in our cohort, and the increased hematologic
malignancy risk was caused by 2 cases of myelodysplastic
syndrome and 2 cases of chronic lymphocytic leukemia. To
what extent these cases are related to CYC-based therapy
or immunosuppression specifically is unclear [32]. In com-
parison, Zycinska et al. found an increased risk of acute
myelogenous leukemia in their study (SIR, 4.3; 95% CI 2.1
to 11.7). Notably, oral CYC was used in the majority of their
patients, and 22% received >36 g of cumulative CYC dosage.
In addition, a significantly increased urothelial cancer risk
was also found in their study, in contrast to those of other
recent groups (SIR, 3.4; 95% CI 1.6 to 5.2) [11].
Some previous groups have indicated that the cancer
risk, perhaps caused by a higher tendency of relapses and
thus higher cumulative immunosuppressive drug doses, is
higher in C-ANCA/PR3-ANCA than in P-ANCA/MPO-
ANCA positive patients [5, 13]. In contrast, we observed no
significantly increased risk in these subgroups compared to
the general population.
An important measure to reduce cancer risk in patients
with AAV has been replacing CYC with azathioprine for
maintenance treatment. This practice change occurred
around 2003 concurrent with the publication of the
CYCAZAREM study [23, 33]. In the present study cohort,
SIR of cancer was not significantly increased, neither in the
1988–2002 nor in the 2003–2012 time periods. Of notice,
in a study including a subgroup of the 1988–2002 cohort,
cumulative doses of CYC were found fairly low, median 17
grams in intravenous CYC-treated patients [34].
The findings by Van Daalen et al. indicate that rituximab
use is associatedwith a substantially lower risk ofmalignancy.
However, this difference was primarily related to excess
NMSC cases.The calculated SIR of cancer, exceptNMSC, was
1.14 (95% CI 0.49 to 2.25) with CYC and 0.88 (95% CI 0.11 to
3.19)with rituximab treatment.Thus, the SIR of cancer, except
NMSC, was only 1.30-fold higher (CI not reported by Van
Daalen et al.) in the CYC group than in the rituximab group.
Further, the SIR of cancer, exceptNMSC, was onlymarginally
higher in the present CYC-treated study cohort than in the
rituximab group in their study, estimated SIR of 0.96 (95%
CI 0.69 to 1.34) and 0.88 (95% CI 0.11 to 3.19), respectively.
Finally, no adjustment for posttransplantation malignancies
has been performed when comparing CYC- and rituximab-
treated patients [19]. In summary, whether replacing low-
dose CYC regimens with rituximab would have a beneficial
effect on non-NMSC malignancy risk remains uncertain.
NMSC occurrence is still substantially increased in
patients with AAV. Although NMSC by no means should be
considered as an inconsequential morbidity, deaths caused
by these tumors are rare [35]. A number of measures can
be taken to reduce the risk and morbidity related to NMSC
in immunosuppressed patients; the most important mea-
sures include limiting sun exposure of the skin and vigilant
monitoring with early NMSC detection and treatment when
they appear. Interestingly, Van Daalen et al. observed that
rituximab use is associatedwith a lowerNMSC risk thanCYC
use, which represents a new possible solution to such com-
plication in patients with AAV [19]. However, the decision
to replace CYC with rituximab as the first-line treatment in
patients with AAV must also include considerations, such as
efficacy, treatment-related complications, and cost-benefit.
The major strengths of the present study include its
population-based approach and identification of patients
with AAV from quality registries with histologic and sero-
logic data. Information on expected and observed cancer
cases was retrieved from the same registry, the Norwegian
Cancer Registry, which limits potential information biases
in the SIR calculation. This registry also has high accuracy
and only few missing cases owing to mandatory reporting of
cancer cases. Moreover, the pooled analysis strengthens the
statistical power and increases the detection rate of significant
differences. Some weaknesses of our study must be admitted.
Most importantly, we could not correlate our findings to the
cumulative CYC doses administered. Treatment data were
unavailable in the NKBR. However, we have shown from pre-
vious reports of this cohort that these patients have received
therapy according to international recommendations [22–
24]. Another weakness is the lack of information regard-
ing extrarenal and relapsing disease. Relapsing disease in
particular is associated with increased treatment length and
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cumulative doses of immunosuppressive drugs that might
affect risk of cancer development. Also, owing to a lack of
sufficient data, we could not calculate pooled SIRs for single-
site cancers or for malignancy after excluding posttransplant
cancers.
In summary, we have demonstrated that the risk of
malignancy in patients with AAV and glomerulonephritis is
not significantly increased. However, significantly increased
NMSC, hematologic malignancy, and posttransplantation
cancer risks were found.These findings indicate the presence
of associations, although relatively weak, between immuno-
suppression and cancer development. However, recently
published data suggest that substituting CYC with rituximab
could eliminate the risk of developing NMSC. Our findings
confirm that the long-term international efforts of developing
CYC-minimizing strategies had an important beneficial effect
on cancer morbidity in patients with AAV.
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[20] I. K. Larsen, M. Småstuen, T. B. Johannesen et al., “Data quality
at the Cancer Registry of Norway: An overview of compa-
rability, completeness, validity and timeliness,” European Jour-
nal of Cancer, vol. 45, no. 7, pp. 1218–1231, 2009.
8 International Journal of Nephrology
[21] A. S. Levey, J. Coresh, T. Greene et al., “Expressing the mod-
ification of diet in renal disease study equation for estimating
glomerular filtration rate with standardized serum creatinine
values,” Clinical Chemistry, vol. 53, no. 4, pp. 766–772, 2007.
[22] K. Aasarod, “Renal histopathology and clinical course in 94
patients with Wegener’s granulomatosis,” Nephrology Dialysis
Transplantation , vol. 16, no. 5, pp. 953–960.
[23] S. Sriskandarajah, K. Aasarød, S. Skrede, T. Knoop, A. V.
Reisæter, and R. Bjørneklett, “Improved prognosis in Norwe-
gian patients with glomerulonephritis associatedwith anti-neu-
trophil cytoplasmic antibodies,”Nephrology Dialysis Transplan-
tation , vol. 30, pp. i67–i75, 2015.
[24] E. Besada, W. Koldingsnes, and J. C. Nossent, “Long-term effi-
cacy and safety of pre-emptive maintenance therapy with ritux-
imab in granulomatosis with polyangiitis: results from a single
centre,” Rheumatology, vol. 52, no. 11, Article ID ket257, pp.
2041–2047, 2013.
[25] J. U. Holle, W. L. Gross, U. Latza et al., “Improved outcome
in 445 patients with Wegener’s granulomatosis in a German
vasculitis center over four decades,” Arthritis & Rheumatology,
vol. 63, no. 1, pp. 257–266, 2011.
[26] N. Reusser, C. Downing, J. Guidry, and S. Tyring, “HPV Car-
cinomas in Immunocompromised Patients,” Journal of Clinical
Medicine, vol. 4, no. 2, pp. 260–281, 2015.
[27] A. E. Grulich, M. T. van Leeuwen, M. O. Falster, and C. M.
Vajdic, “Incidence of cancers in people with HIV/AIDS com-
pared with immunosuppressed transplant recipients: a meta-
analysis,”The Lancet, vol. 370, no. 9581, pp. 59–67, 2007.
[28] E. N. Pritchett, A. Doyle, C. M. Shaver et al., “Nonmelanoma
skin cancer in nonwhite organ transplant recipients,” JAMA
Dermatology, vol. 152, no. 12, pp. 1348–1353, 2016.
[29] S. Euvrard, J. Kanitakis, andA. Claudy, “Skin cancers after organ
transplantation,”TheNew England Journal of Medicine, vol. 348,
no. 17, pp. 1681–1691, 2003.
[30] P. O’Donovan, C. M. Perrett, and X. Zhang, “Azathioprine and
UVA light generatemutagenic oxidative DNAdamage,” Science,
vol. 309, no. 5742, pp. 1871–1874, 2005.
[31] J. Pedersen-Bjergaard, S. Olesen Larsen, J. Struck et al., “Risk
of therapy-related leukaemia and preleukaemia after Hodgkin’s
disease. Relation to age, cumulative dose of alkylating agents,
and time from chemotherapy,” The Lancet, vol. 330, no. 8550,
pp. 83–88, 1987.
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